MorphoSys to provide Army with antibodies to study biological threats

By E. Janene Geiss

Philadelphia, Sept. 25 - MorphoSys AG said Monday that its business unit, AbD Serotec, has won a contract as sole source on a biodefense-related project by the USAMRIID, an organization of the U.S. Army Medical Research and Materiel Command and lead medical research laboratory for the U.S. Biological Defense Program.

The USAMRIID, which conducts basic and applied research on biological threats, has ordered fully human recombinant research antibodies against five bacterial-derived toxins, the Munich, Germany, biotechnology company said in a news release.

AbD Serotec will generate these antibodies using the HuCAL GOLD antibody library developed by MorphoSys. Financial details of the agreement were not disclosed.

Biological toxins derived from living organisms, such as bacteria and other micro-organisms or plants, are biological agents with potential implications in bioterrorism. HuCAL-derived antibodies may support the development of countermeasures against such biological toxins or act as therapeutic agents themselves.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.